Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Rosiglitazone inhibits Kv4.3 potassium channels by open-channel block and acceleration of closed-state inactivation.

Jeong I, Choi BH, Hahn SJ.

Br J Pharmacol. 2011 Jun;163(3):510-20. doi: 10.1111/j.1476-5381.2011.01210.x.

2.

Diabetes: Breaking news! Rosiglitazone and cardiovascular risk.

Kaul S, Diamond GA.

Nat Rev Cardiol. 2010 Dec;7(12):670-2. doi: 10.1038/nrcardio.2010.160. No abstract available.

PMID:
21102630
3.
4.

Thiazolidinediones and cardiovascular risk - a question of balance.

Erdmann E, Charbonnel B, Wilcox R.

Curr Cardiol Rev. 2009 Aug;5(3):155-65. doi: 10.2174/157340309788970333.

5.

Pharmacokinetic and bioequivalence study of an oral 8 mg dose of rosiglitazone tablets in Thai healthy volunteers.

Wittayalertpanya S, Chompootaweep S, Thaworn N, Khemsri W, Intanil N.

J Med Assoc Thai. 2010 Jun;93(6):722-8.

PMID:
20572378
6.
7.

Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation.

Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH; American Heart Association; American College Of Cardiology Foundation.

J Am Coll Cardiol. 2010 Apr 27;55(17):1885-94. doi: 10.1016/j.jacc.2010.02.014. No abstract available.

8.

Medicinal chemistry of drugs used in diabetic cardiomyopathy.

Adeghate E, Kalasz H, Veress G, Teke K.

Curr Med Chem. 2010;17(6):517-51. Review.

PMID:
20015035
9.

Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing?

Mannucci E, Monami M.

Curr Diab Rep. 2009 Oct;9(5):342-7. Review.

PMID:
19793503
10.

Peroxisome proliferator-activated receptor gamma antagonists decrease Na+ transport via the epithelial Na+ channel.

Pavlov TS, Levchenko V, Karpushev AV, Vandewalle A, Staruschenko A.

Mol Pharmacol. 2009 Dec;76(6):1333-40. doi: 10.1124/mol.109.056911. Epub 2009 Sep 14.

11.

Electrophysiological characteristics of heart ventricular papillary muscles in diabetic histidine decarboxylase knockout and wild-type mice.

Szebeni A, Falus A, Kecskeméti V.

J Interv Card Electrophysiol. 2009 Dec;26(3):155-8. doi: 10.1007/s10840-009-9432-5.

PMID:
19731003
12.

Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume.

Acton JJ 3rd, Akiyama TE, Chang CH, Colwell L, Debenham S, Doebber T, Einstein M, Liu K, McCann ME, Moller DE, Muise ES, Tan Y, Thompson JR, Wong KK, Wu M, Xu L, Meinke PT, Berger JP, Wood HB.

J Med Chem. 2009 Jul 9;52(13):3846-54. doi: 10.1021/jm900097m. Erratum in: J Med Chem. 2013 Nov 27;56(22):9368. Tan, Yugen [corrected to Tan, Yejun].

PMID:
19507861
13.

Distinct modulation of voltage-gated and ligand-gated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons.

Pancani T, Phelps JT, Searcy JL, Kilgore MW, Chen KC, Porter NM, Thibault O.

J Neurochem. 2009 Jun;109(6):1800-11. doi: 10.1111/j.1471-4159.2009.06107.x. Epub 2009 May 11.

14.

Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.

Krentz A.

Diabetes Metab Res Rev. 2009 Feb;25(2):112-26. doi: 10.1002/dmrr.937. Review.

PMID:
19219860
15.

Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.

Larsen PJ, Lykkegaard K, Larsen LK, Fleckner J, Sauerberg P, Wassermann K, Wulff EM.

Eur J Pharmacol. 2008 Oct 31;596(1-3):173-9. doi: 10.1016/j.ejphar.2008.08.004. Epub 2008 Aug 16.

PMID:
18761337
16.

Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction.

Giles TD, Miller AB, Elkayam U, Bhattacharya M, Perez A.

J Card Fail. 2008 Aug;14(6):445-52. doi: 10.1016/j.cardfail.2008.02.007. Epub 2008 May 27.

PMID:
18672190
17.

Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality.

Wilson KD, Li Z, Wagner R, Yue P, Tsao P, Nestorova G, Huang M, Hirschberg DL, Yock PG, Quertermous T, Wu JC.

PLoS One. 2008 Jul 9;3(7):e2609. doi: 10.1371/journal.pone.0002609.

18.

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM; PERISCOPE Investigators.

JAMA. 2008 Apr 2;299(13):1561-73. doi: 10.1001/jama.299.13.1561. Epub 2008 Mar 31.

PMID:
18378631
19.

Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.

DREAM Trial Investigators, Dagenais GR, Gerstein HC, Holman R, Budaj A, Escalante A, Hedner T, Keltai M, Lonn E, McFarlane S, McQueen M, Teo K, Sheridan P, Bosch J, Pogue J, Yusuf S.

Diabetes Care. 2008 May;31(5):1007-14. doi: 10.2337/dc07-1868. Epub 2008 Feb 11.

PMID:
18268075
20.

Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs.

Lu L, Reiter MJ, Xu Y, Chicco A, Greyson CR, Schwartz GG.

Diabetologia. 2008 Apr;51(4):675-85. doi: 10.1007/s00125-008-0924-0. Epub 2008 Feb 5.

Items per page

Supplemental Content

Write to the Help Desk